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The deoxycytidine deaminase APOBEC3G (A3G) is expressed in human T cells and inhibits HIV-1 replication. When
transfected into A3G-deficient epithelial cell lines, A3G induces catastrophic hypermutation by deaminating the HIV-1
genome. Interestingly, studies suggest that endogenous A3G in T cells induces less hypermutation than would be
expected. However, to date, the specific deaminase activity of endogenous A3G in human CD4þ T cells has not been
examined directly. Here, we compared deaminase activity of endogenous and exogenous A3G in various human cell
lines using a standard assay and a novel, quantitative, high-throughput assay. Exogenous A3G in epithelial cell lysates
displayed deaminase activity only following RNase treatment, as expected given that A3G is known to form an
enzymatically inactive RNA-containing complex. Surprisingly, comparable amounts of endogenous A3G from T cell
lines or from resting or activated primary CD4þT cells exhibited minimal deaminase activity, despite RNase treatment.
Specific deaminase activity of endogenous A3G in H9, CEM, and other T cell lines was up to 36-fold lower than specific
activity of exogenous A3G in epithelial-derived cell lines. Furthermore, RNase-treated T cell lysates conferred a dose-
dependent inhibition to epithelial cell lysates expressing enzymatically active A3G. These studies suggest that T cells,
unlike epithelial-derived cell lines, express an unidentified RNase-resistant factor that inhibits A3G deaminase activity.
This factor could be responsible for reduced levels of hypermutation in T cells, and its identification and blockade
could offer a means for increasing antiretroviral intrinsic immunity of T cells.
Citation: Thielen BK, Klein KC, Walker LW, Rieck M, Buckner JH, et al. (2007) T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog 3(9):
e135. doi:10.1371/journal.ppat.0030135
Introduction
Viral infection represents a common threat faced by most
cells, and different cell types have evolved unique strategies
for defending against viral pathogens. One such strategy
involves the deoxycytidine deaminase APOBEC3G (A3G), an
intrinsic defense mechanism speciﬁc to primates. A3G is a
cellular protein expressed in a limited number of cell types
[1,2], including, but not limited to, T cells and macrophages,
and has antiviral activity against HIV-1, hepatitis B virus, and
endogenous retroelements (reviewed in [3]). During HIV-1
infection, A3G can exert antiviral effects either when it is
packaged into virions (reviewed in [4]) or when it is present in
T cells [5], which are a natural target of infection. The
antiviral effect of packaged A3G is not observed in infections
with wild-type virus because HIV encodes the viral infectivity
factor (Vif), which prevents A3G from being packaged into
newly formed virus particles by targeting it for proteosomal
degradation [6–9] and by other mechanisms [10]. However, in
the absence of functional Vif, A3G is packaged and
subsequently mediates deamination of deoxycytidine (dC)
residues in the nascent minus-strand DNA during reverse
transcription of the HIV genome. As a result of this
deamination, G-to-A hypermutation of the coding strand
can occur, resulting in an increased proportion of non-
infectious virus (reviewed in [4]). Alternatively, the presence of
multiple deoxyuridines (dUs) in the minus strand may prevent
accumulation of reverse transcripts, either by triggering
degradation by cellular DNA repair machinery [11–13] or by
impairing synthesis [14,15]. In both cases, dC-to-dU deami-
nation was initially thought to be critical to the antiviral
effects of packaged A3G. However, subsequent studies have
demonstrated that packaged A3G mutants can have antiviral
effects even when they lack deaminase activity [16–19].
Recent studies also indicate that A3G does not always need
to be packaged to inhibit HIV infection. Endogenous A3G
present in resting CD4þ T cells from peripheral blood, but
not from lymphoid tissue, restricts infection of these cells in a
Vif-independent manner [5,20]. Interestingly, when reverse
transcripts from these cells were examined, unexpectedly low
levels of hypermutation were observed [5], raising the
possibility that A3G-mediated restriction of infection of
resting T cells may also occur by mechanisms other than
deamination. Thus, both packaged A3G and A3G present in
resting T cells may restrict HIV-1 infection by a deaminase-
independent mechanism, although in both cases some degree
of mutation of HIV reverse transcripts is typically seen.
To determine how much deamination contributes to the
antiviral effect of A3G in vivo, a better understanding of the
deaminase activity of endogenous A3G in T cells and
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activity has been studied primarily using tagged A3G ex-
pressed exogenously in epithelial cell lines. In these cells,
exogenously expressed A3G is found in high molecular mass
(HMM) ribonucleoprotein complexes, which are enzymati-
cally inactive. RNase A treatment of epithelial cell lysates
disrupts the integrity of these complexes, producing an
enzymatically active, low molecular mass (LMM) form of A3G
[5,20,21]. RNase-sensitive HMM complexes are also found in
T cell lines, activated CD4þT cells, resting CD4þT cells from
lymphoid tissue, and CD16þ monocytes, all of which are
susceptible to infection by wild-type HIV-1. Interestingly,
resting peripheral blood CD4þT cells and CD16- monocytes,
which restrict HIV-1 infection, contain primarily LMM A3G
[5,20–22]. However, to date, no studies have examined
enzymatic activity of endogenous A3G in resting or activated
CD4þ T cells. Although the ﬁnding that LMM A3G in resting
T cells confers resistance to HIV infection demonstrates its
antiviral activity, the surprisingly low percentage of mutated
HIV reverse transcripts recovered from these cells [5] raises
the possibility that A3G may not be as enzymatically active in
resting T cells as it is in epithelial cell lines. Here, we
demonstrate that the deaminase activity of LMM A3G in T
cells is much lower than the deaminase activity of comparable
amounts of exogenous A3G expressed in epithelial cells.
These data suggest that endogenous A3G in T cells is
regulated by a novel inhibitory protein or proteins. This
inhibition of A3G deaminase activity could explain the
unexpectedly low level of HIV hypermutation observed in
resting T cells [5]. Such a mechanism for regulation in cells
expressing endogenous A3G in the LMM form could allow for
more ﬁne-tuned modulation of this enzyme that may be
harmful to the cell if uncontrolled but is also needed for
defense against viruses and endogenous retroelements [23].
Results
To determine if A3G activity is regulated differently in T
cells and epithelial cells, we compared the activity of
endogenous A3G in human T cell lines (H9 cells and H9
cells expressing the HIV genome without Vif) to the activity
of comparable amounts of exogenous A3G expressed in
human epithelial-derived cell lines (293FT and HeLa cells)
using a standard gel-based deaminase assay, in which an
infrared 700 (IRDye 700)–labeled oligonucleotide containing
the A3G deamination motif (dCdC) was incubated with
samples of total cell extracts containing 10 lg of total cellular
protein. Uracil DNA glycosylases (UDGs) present endoge-
nously in cell extracts and recombinant UDG added to the
assay convert deaminated dCs to abasic sites, which are
cleaved during the assay upon incubation at a basic pH (see
Figure S1A). The resulting oligonucleotide cleavage is then
detected by gel electrophoresis followed by imaging with a LI-
COR infrared scanner. While incubation of the oligonucleo-
tide with RNase A–treated epithelial cell extracts expressing
A3G resulted in high levels of cleavage in the absence or
presence of exogenous UDG, incubation with RNase A–
treated H9 cell extracts resulted in much less oligonucleotide
cleavage, even in the presence of exogenous UDG (Figure 1A).
An aliquot of each cell lysate subjected to immunoblotting for
A3G conﬁrmed the presence of similar amounts of A3G in
lysates of H9 cells and transfected 293FT (Figure 1A). The
surprising ﬁnding that endogenous A3G in the T cell extracts
exhibited less deaminase activity than comparable amounts
of transfected A3G in epithelial cells raised the possibility
that an inhibitory activity exists in H9 T cells. Since two
enzymatic reactions occur in this assay (deamination by A3G
and base excision by UDG), a parallel control was performed
to determine which of the two reactions was inhibited in H9
cells. When an IR-labeled oligonucleotide containing dU was
incubated with the same cell extracts in the presence of
RNase A but without exogenous UDG, it was cleaved to a
similar extent across cells types (Figure 1B), indicating
equivalent endogenous UDG-mediated base excision in H9
T cell lines and epithelial cell lines. These data are consistent
with previous reports [24] and indicate that H9 extracts do
not contain an inhibitor of UDG activity. Together, these
ﬁndings suggested that after RNase A treatment, endogenous
A3G in H9 T cells exhibits less A3G deaminase activity than
comparable amounts of transfected A3G expressed in 293FT
cells. Since improved and nearly complete cleavage was
observed in all cell types upon supplementation with
exogenous UDG, all future studies were performed in the
presence of exogenous UDG.
To quantify A3G activity accurately, it would be important
to use an assay that yields activity measurements proportional
to the amount of A3G input over a wide range of enzyme
amounts. The time- and labor-intensive gel-based assay is not
readily amenable to the multiple measurements that are
required to validate linearity of the assay for a large number
of cell types. Thus, to obtain a more quantitative view of A3G
deaminase activity in different cell types, we developed a
ﬂuorescence resonance energy transfer (FRET)–based, high-
throughput assay that would allow us to more easily perform
dose-response curves and multiple replicates using either
crude cell extracts or immunoprecipitated A3G. The lack of
simple, non-radioactive, quantitative assays has been at least
partially responsible for the absence of comprehensive
studies of A3G activity in a wide variety of cell types and
physiological situations. Although many studies examine G-
to-A mutation rates by either E. coli–based mutation assays
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Author Summary
APOBEC3G (A3G) is an antiviral enzyme that is expressed in human T
cells and macrophages, which are the cell types infected by HIV.
Early in the HIV life cycle, the HIV RNA genome is reverse transcribed
into DNA. A3G can modify this DNA enzymatically, leading to high
rates of mutation such that the virus can no longer replicate. To
date, most studies of A3G’s enzymatic activity have utilized cell lines
(293T and HeLa) that can be transfected to express A3G but do not
express it endogenously. A report of unexpectedly low levels of
mutation in viral DNA from HIV-infected human T cells led us to
investigate regulation of A3G enzymatic activity in T cells. We
developed a high-throughput assay to compare the enzymatic
activity of endogenous A3G in T cells versus transfected (exogenous)
A3G. Surprisingly, enzymatic activity of A3G from human T cell lines
and primary T cells was very low relative to A3G from transfected
cells, even when corrected for A3G protein amount. Moreover, T cell
lysates inhibited enzymatic activity of exogenously expressed A3G.
These data suggest that enzymatic activity of endogenous A3G in
human T cells is inhibited by an uncharacterized mechanism that
may protect the host from this DNA mutator and could have
important implications for A3G antiviral activity in vivo.[17,18,25,26] or sequencing the HIV provirus [5,16,27,28],
such assays reﬂect A3G deaminase activity only indirectly.
One method for directly assaying A3G deaminase activity
measures the ability of immunoprecipitated or virion-
incorporated A3G to induce deamination-dependent cleav-
age of
32P-labeled oligonucleotides, as detected by altered
migration on a gel [5,26,29]. Alternatively, incorporation of
3H - l a b e l e dd A T P ,w h i c ho n l yo c c u r sw h e nd C si na n
oligonucleotide template strand are converted to dUs by
deamination, can be measured [30,31]. We devised a non-
radioactive assay in which the A3G substrate is a 13-base
oligonucleotide that contains the A3G recognition motif and
is dual-labeled with FRET-optimized ﬂuorophores. We added
exogenous UDG to ensure complete uracil excision. Treat-
ment with base leads to cleavage of the labeled oligonucleo-
tide at sites of deamination, as in the gel-based assay. Upon
cleavage, the reporter ﬂuorophore is no longer efﬁciently
quenched, producing an increase in detectable ﬂuorescence
(Figure S1A). Using different ratios of double- and single-
labeled oligos (Table S1), we demonstrated that ﬂuorescence
is directly proportional to the amount of single-labeled oligo
representing cleaved substrate (Figure S1B).
We then validated the FRET-based assay by demonstrating
that increasing A3G expression in 293FT cells resulted in a
dose-dependent increase in deaminase activity when the assay
was performed with extracts from cells expressing increasing
amounts of A3G plasmid, but only in the presence of RNase A
(Figure S2A). These data are consistent with previous reports
that A3G in 293T cells is only active as a deaminase after
conversion from the HMM to LMM form using RNase A [5].
Dose dependence was also observed when the deaminase
assay was performed with increasing amounts of cell lysate
from 293FT cells transfected with a ﬁxed amount of A3G
plasmid and when the length of oligonucleotides containing
the A3G cleavage site was varied (Figure S2B). The consistent
low level of cleavage that was detected in cell lysates lacking
signiﬁcant A3G expression (Figures S2A and S2B) is likely
due, at least in part, to other cytidine deaminase enzymes,
given that the degree of cleavage induced by incubation with
crude cell lysates lacking A3G was greater for CCC-containing
oligos than for GGG-containing oligos (Figure S2A). While
speciﬁc antibodies are not available for most APOBEC3
family members, we were able to assess A3F levels using an
antibody that speciﬁcally recognizes A3F and not A3G (Figure
S2C). In some experiments, we detected expression of
APOBEC3F (A3F) in non-transfected 293FT cells, albeit at
low levels (unpublished data). This may account for the A3G-
independent baseline activity we observed in these cells since
some of our oligos (shown in Table S1) also contain the TC
dinucleotide motif recognized by A3F [32]. Nevertheless, we
consistently observed activity above background levels that
was mediated by A3G in a dose-dependent manner and
Figure 1. A Gel-Based Assay Reveals That Endogenous A3G in T Cell
Lines Exhibits Unexpectedly Low Deaminase Activity Compared to
Exogenous A3G in Transfected Epithelial-Derived Cell Lines
(A) Deaminase activity was measured using an infrared 700 (IR700)–
labeled oligo containing the A3G recognition site (CCC) either with or
without exogenous recombinant uracil DNA glycosylase (þ/- UDG).
Oligos were incubated with crude cell lysates containing 10 lg of total
cellular protein obtained from H9 cells, H9 cells expressing the HIV
genome containing a deletion in Vif (H9-HIV), or from HeLa or 293FT cells
transfected with the indicated amounts of A3G plasmid DNA (pA3G).
Extent of oligo cleavage (indicating extent of deamination) was
determined by gel electrophoresis followed by detection on a LI-COR
scanner (top panel), and the percentage of probe cleaved was graphed
(second panel). Below, equivalent amounts of cell lysate were analyzed in
parallel by western blot (WB) to show A3G protein content. Western blot
of calreticulin is shown as a loading control.
(B) UDG activity was measured in select lysates from (A) using an IR700-
labeled dU-containing oligo in the presence or absence of exogenous
UDG (þ/- UDG). Results are displayed as in (A) and show that unlike A3G
activity shown in (A), UDG activity is similar in all cell lysates analyzed.
All assays were performed on RNAse A–treated samples.
doi:10.1371/journal.ppat.0030135.g001
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rescence units (RFU). Additionally, although others have
reported a minimum length requirement of 16 bases for oligo
binding by puriﬁed recombinant A3G [33], we were able to
detect deamination by A3G from cell extracts using the
FRET-based assay with oligos of 13 to 21 bases in length
(Figure S2B; unpublished data).
To measure the activity of A3G in the absence of cellular
nucleases and other deaminases, we subjected lysates from
293FT cells transfected with A3G to immunoprecipitation
with beads coupled to either afﬁnity-puriﬁed A3G-speciﬁc
antiserum (aA3G) or rabbit IgG under native conditions
before (Figure S2D) or after (unpublished data) RNase A
treatment. Using either approach, enzymatically active A3G
was efﬁciently recovered following immunoprecipitation with
aA3G, and increasing amounts of immunoprecipitation
eluate resulted in a dose-dependent increase in A3G activity
spanning a range of 833 RFU. Note that the A3G antiserum
most likely immunoprecipitates A3G speciﬁcally since it is
directed against the C-terminus of A3G, which differs
considerably from the C-termini of other APOBEC family
members. Consistent with this, A3G immunoprecipitation
completely eliminates the baseline A3G-independent deam-
ination activity that is observed when activity is measured in
crude cell lysates (compare Figure S2D with Figure S2A and
S2B). Finally, to further validate the FRET-based assay, we
demonstrated that two A3G mutants that contain substitu-
tions in both deaminase domains and are known to display
substantially reduced enzymatic activity in E. coli–based
mutation assays [17] also displayed 30- to 50-fold less activity
than wild-type A3G in the FRET-based assay (Figure S2E).
Thus, taken together, these results demonstrate that the
FRET-based assay speciﬁcally detects catalytically active,
exogenously expressed A3G from both crude cell lysates
and immunoprecipitations over a dynamic range of 800 to
1,100 RFU.
Using our quantitative FRET-based assay for A3G activity,
we asked whether A3G expressed endogenously in human cell
lines exhibits similar levels of deaminase activity as A3G
transfected into epithelial cells. For this purpose we used two
human T cell lines: the H9 cells, described above, as well as
CEM cells, which also express native A3G, albeit at lower
levels than H9 cells. Moreover, for each T cell line, we chose
input cell lysate amounts that were matched for A3G content
with samples from transfected 293FT cells displaying high
deaminase activity (i.e., transfected with 30–100 ng of A3G
plasmid). As expected, transfected A3G in 293FT cell lysate
exhibited a dose-dependent increase in deaminase activity
Figure 2. A Quantitative FRET-Based Assay Reveals That Endogenous
A3G in T Cell Lines Exhibits Very Low Specific Deaminase Activity
Compared to Transfected A3G Expressed in Epithelial-Derived Cell Lines
(A) Deaminase activity of crude cell lysates from H9 and CEM T cell lines or
from 293FT cells transfected with the indicated amounts of A3G plasmid
DNA (pA3G) was determined as RFU using the FRET-based assay and was
graphed. Variable amounts of total cellular protein inputs were used as
indicated (lg protein) to match the total amount of endogenous A3G from
T cell lines with the highest level of transfected A3G in 293FT cells of
epithelial origin. Below, western blots (WB) show amount of A3G input for
all samples, as well as amount of calreticulin as a reference for amount of
total protein input. Statistical significance *, p , 0.01 relative to 293FT, 100
ng; **, p , 0.01relative to293FT, 30ng.Background fluorescenceobtained
for each sample using the 13-mer GGG-containing oligonucleotide was
subtracted from the signal detected using the 13-mer CCC-containing
substrate. Error bars represent standard error of the mean of triplicate
reactions. Note that when the A3G dose-response deaminase activity
values for each 293FT sample were graphed relative to amounts of A3G
protein in those samples determined by densitometry, a linear relationship
with a correlation coefficient of 0.99 was observed (unpublished data).
(B) Specific A3G deaminase activity (RFU/ng A3G protein) of A3G
expressed endogenously in T cells or expressed exogenously by
transfection in HeLa cells was calculated from a typical experiment, as
shown in Figure S3, and was graphed. Statistical significance *, p , 0.05
relative to HeLa control.
(C) Cell lysates from A3G expressing 293FT and H9 cells þ/- RNase A
treatment were subjected to velocity sedimentation, fractionated (1–12),
and analyzed by western blotting with antibody to A3G. Western blots
show that RNase treatment was effective in converting HMM A3G to
LMM A3G in all cell types analyzed. Brackets indicate migration of A3G
HMM and LMM complexes.
All panels are representative of at least three independent experiments.
All FRET assays were performed with RNase A. Numbers on/above bars in
(A and B) indicate actual values graphed.
doi:10.1371/journal.ppat.0030135.g002
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Inhibitor of A3G in T Cellsthat was proportional to the relative amounts of A3G protein
expressed by transfecting increasing amounts of plasmid
DNA (Figure 2A). However, the signal produced by RNase-
treated H9 cell lysate was 15-fold less than the signal
produced by the lysate of 293FT cells containing a compa-
rable amount of transfected A3G that was treated with RNase
A and assayed in parallel (Figure 2A; 43 RFU versus 678 RFU),
consistent with what was found with the gel-based assay
(Figure 1A). Similarly, RNase-treated CEM cell lysate pro-
duced a signal that was 30-fold less than a comparable
amount of A3G expressed by transfection of 293FT cells
(Figure 2A; 17 RFU versus 508 RFU). As expected, the amount
of input cell lysate needed to achieve these levels of A3G was
higher for CEM cells (as indicated by higher levels of the
calreticulin loading control) due to their relatively low level
of A3G expression [34].
To compare deaminase activity in different cell types, we
determined the speciﬁc activity of A3G in each cell type. We
ﬁrst determined the amount of A3G expressed at steady state
in T cell lines and transfected HeLa cells by interpolation on
a standard curve generated by parallel immunoblotting of
aliquots of samples and known amounts of recombinant
standards (Figure S3A). H9 and CEM cells contained
approximately 2.9 and 2.0 ng A3G/lgc e l l u l a rp r o t e i n ,
respectively, which was similar to the amount of A3G
expressed in the transfected HeLa control (Figure S3). We
then calculated speciﬁc deaminase activity (deaminase activ-
ity per unit A3G protein) by normalizing the deaminase
activity of each sample to the amount of A3G protein in each
sample (Figure S3B), and found that the speciﬁc deaminase
activity of endogenously expressed A3G in T cell lines was 36-
fold lower than that of A3G transfected into HeLa cells
(Figure 2B). Thus, even when normalized for A3G protein
levels, deaminase activity appears to be inhibited in T cells.
Previous work showed that RNase treatment was needed to
dissociate HMM complexes, which in turn was required for
A3G enzymatic activity [5]. While the concentration of RNase
A we used in the experiments reported here (250 lg/ml) was
5-fold greater than that used by others to dissociate HMM
complexes [5] and 250-fold above that needed to reduce
cellular RNA levels by 1,000-fold [35], we wanted to verify that
RNase treatment was indeed disrupting HMM complexes in T
cells, given their lower level of deaminase activity. Velocity
sedimentation gradients demonstrated that RNase A con-
verted A3G in T cell lines from an HMM form to an LMM
form (Figure 2C), indicating the effectiveness of the RNase A
treatment. Thus, the low A3G activity in T cells is not due to
A3G being retained in the HMM complex.
Since different T cell lines express signiﬁcantly different
amounts of A3G, we examined expression of A3G in several
other T cell and monocyte lines by immunoblotting.
Although many expressed little or no A3G (SupT1, U937,
MOLT4, CEMSS, C8166) and others expressed low levels of
A3G (CEM, Jurkat, A3.01), two cell lines (HSB2 and Hut 78)
displayed levels of A3G similar to that of H9 cells (Figure 3A).
Notably, the relative amounts of A3G protein seen by
immunoblotting correlated well with the relative amounts
of A3G mRNA observed by others in these cell lines [34,36].
We examined the amount of deaminase activity in cell lines
whose A3G amounts were within 2-fold of the amount of A3G
observed in transfected 293FT cells. Despite excellent
endogenous A3G expression, HSB2 and Hut78 cells, like H9
T cells, exhibited very little deaminase activity, even when
assayed over a 20-fold range of total protein input (Figure
3B). Note that transfected A3G expressed in 293FT cells
displays a linear increase in activity over approximately a 10-
fold range of input amounts, with activity then reaching a
plateau consistent with saturation of the assay. When activity
was normalized for A3G protein levels, we found that A3G
from 293FTs had a speciﬁc deaminase activity of 6.1 RFU/ng
A3G, while speciﬁc deaminase activity for A3G from all T cell
lines tested was signiﬁcantly lower, ranging from 0.32 to 0.91
RFU/ng A3G (Figure 3C). Similar results were observed in
lysates prepared in the presence (unpublished data) or
absence (Figure 3C) of EDTA, and with (Figure 3C) or
without (unpublished data) DNase treatment. Moreover,
because the assay involves incubation of lysates for over an
hour at 37 8C, we considered the possibility that degradation
of A3G could occur over the course of the assay despite the
use of a protease inhibitor cocktail during cell harvest, and
that this could be more prominent in T cells than in other cell
types. However, when aliquots of the assay were removed at
the start (0 min) and during the assay (30, 60, and 90 min), no
change was seen in the amount of A3G or calreticulin during
the 37 8C incubation in H9, HSB2, Hut78, or transfected
293FT cell lines (Figure 3D), ruling out selective A3G
degradation as a cause of the very low deaminase activity
levels in T cell lines. Thus, several different T cell lines that
express signiﬁcant amounts of A3G exhibited very low
speciﬁc activity compared to exogenous A3G expressed in
293FT cell lines, and these differences could not be explained
by assay conditions or other experimental parameters.
To conﬁrm that A3G or A3G-containing complexes are
responsible for the ﬁndings obtained with crude cell lysates,
we isolated A3G and associated proteins from other cellular
components by immunoprecipitation with an antibody
speciﬁc to A3G followed by elution under native conditions.
To dissociate HMM complexes, immunoprecipitates were
treated with RNase A. Again, despite RNase A treatment and
the presence of similar amounts of A3G protein in the
immunoprecipitation eluates, A3G immunoprecipitated
from H9 and CEM cells displayed signiﬁcantly less deaminase
activity than A3G from 293FT cells (Figure 4A), suggesting
that LMM A3G from T cells is less active than LMM A3G from
transfected epithelial cell lines. Similar results were seen
when lysates were pre-treated with RNase A prior to
immunoprecipitation and when activity assays were per-
formed directly on immunoprecipitation beads (unpublished
data). No activity above baseline was seen in the correspond-
ing H9 or CEM crude cell lysates or in immunoprecipitations
that were not subjected to RNase treatment (unpublished
data). SupT1, a T cell line that does not express A3G mRNA
[34,36], lacked A3G protein by immunoblotting and did not
display deaminase activity in our assay, as expected (unpub-
lished data). Although the amount of A3G protein in the
eluates from T cells was very similar to that of control 293FT
cells, the speciﬁc activity of endogenous A3G immunopreci-
pitated from T cell lines was 7.8- to 22-fold lower than that of
A3G transfected into 293FT cells (Figure 4B). Notably, little
difference in A3G-speciﬁc activity was observed when A3G
was immunoprecipitated from RNase A–treated lysates of
parental H9 T cells versus H9 T cells stably expressing a Vif-
deleted HIV-1 genomic construct (Figure 4B), indicating that
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ingly low activity of A3G immunoprecipitated from H9 cells.
Finally, we examined the deaminase activity of endogenous
A3G in primary human T cells. RNase A–treated cell lysates
from both resting and activated CD4þ primary cells puriﬁed
from peripheral blood exhibited much lower levels of
deaminase activity than input cell lysates from 293FT cells
containing equivalent amounts of A3G (Figure 5A, compare
immunoblots of resting and activated CD4þ T cells to 293FT
cells transfected with 10 ng and 30 ng A3G, respectively).
Similar results were obtained when resting and activated
CD4þ T cells were not treated with RNase A (unpublished
data). Additionally, upon immunoprecipitation and RNase A
treatment, minimal deaminase activity was detected in resting
and activated CD4þT cells, respectively, compared to similar
amounts of immunoprecipitated A3G from 293FT cells
(Figure 5B). Thus, the deaminase activity of endogenous
A3G present in unstimulated and stimulated primary human
CD4þ T cells was also inhibited relative to the deaminase
activity of A3G transfected into epithelial cell lines, as was
observed above for endogenous A3G in four human T cell
lines. This was particularly surprising given that we and
others [5] have observed that A3G in resting T cells is in the
LMM form even in the absence of RNase treatment (Figure
5C). Thus, in T cell lines and in primary T cells, activity of
LMM A3G is much lower than expected, and this low activity
is most likely not attributable to inhibitory RNA since the low
activity is observed even after RNase A treatment.
The low speciﬁc activity of A3G in T cells suggested three
possible models: (1) T cells contain a less active isoform of
A3G, (2) epithelial cell lines contain an activator of A3G that
is absent or at lower levels in T cells, or (3) an inhibitor of
A3G deaminase activity is present in T cells but not in
epithelial cell lines (or is present in T cells at signiﬁcantly
higher levels). When we transfected 293FT cells with plasmids
representing human A3G sequence variants that differ at two
amino acid positions, one derived from A3G cDNA ampliﬁed
Figure 3. Other T Cell Lines with High Levels of Endogenous A3G Protein
Exhibit Very Low Specific Deaminase Activity
(A) Endogenous A3G protein levels from the indicated T cell lines,
compared to 293FT cells mock-transfected (0 ng 293FT) or transfected
with 10 ng A3G plasmid DNA, were determined by western blotting (WB)
in two independent experiments (top versus bottom panels). Western
blots of calreticulin are shown as a loading control. Amount of A3G
protein (ng) is indicated in each lane, as determined by densitometry
relative to recombinant A3G protein standards that are not shown.
(B) Deaminase activity of different amounts RNase A–treated crude cell
lysates either from A3G-expressing T cells or from 293FT cells transfected
with 0 or 10 ng of A3G plasmid DNA (pA3G) was determined using the
FRET-based assay and was graphed. Amounts of input cell lysate are
indicated by lg of total cellular protein. Error bars represent standard
error of the mean of triplicate reactions. Below, western blots show
relative amounts of A3G compared to the loading control calreticulin for
each cell type.
(C) Specific deaminase activity of A3G (RFU/ng A3G protein) was
calculated for DNase-treated lysates of H9, HSB2, and Hut78 cells, as well
as for 293FT cells transfected with 50 ng A3G plasmid DNA (50 ng 293FT)
from a representative experiment and were graphed. Below, western
blots show the amount of A3G in each cell lysate and in known
recombinant standards (rA3G), which were used to determine protein
amounts for specific deaminase activity calculations, as described in
Figure S3. Numbers on/above bars indicate actual values graphed.
(D) Western blots show the amount of A3G and calreticulin in equivalent
amounts of crude cell lysates from H9, HSB2, and Hut78 T cells or from
293FT cells transfected with the indicated amounts of A3G plasmid DNA
(pA3G) and incubated for 0, 30, 60, and 90 min at 37 8C (increased time
from left to right). Corresponding A3G activity was determined for all
time points using the FRET-based assay, and the maximal activity (90
min) is graphed above. Background fluorescence for each sample using
the 13-mer GGG-containing oligonucleotide was subtracted from signal
detected with the 13-mer CCC-containing substrate for all FRET
deaminase assays. Numbers on/above bars indicate actual values
graphed.
All panels are representative of three independent experiments. All FRET
assays were performed with RNase A.
doi:10.1371/journal.ppat.0030135.g003
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Inhibitor of A3G in T Cellsfrom a CEM T cell line ([34]) and the other from A3G cDNA
ampliﬁed from human kidney cells ([10]), we obtained similar
deaminase-speciﬁc activity values (unpublished data), which
argues against an inactive isoform present in T cells. To
further distinguish among these possibilities, we ﬁrst mixed
lysate from non-transfected 293FT cells with lysate from H9
cells expressing endogenous A3G. Endogenous A3G activity
from H9 cells was unchanged (unpublished data), suggesting
that the activity observed in 293FT cells is not due to the
presence of an activating factor. We next examined whether
inhibition could be conferred to A3G-expressing 293FT
lysates by simply adding lysates of human T cell lines. To
keep A3G levels constant in these mixing experiments, we
only added lysate from T cell lines (or control epithelial cell
lines) that lacked detectable amounts of A3G. All lysates were
RNase-treated in this experiment. First, we pre-incubated
lysate from the A3G-deﬁcient MOLT4 human T cell line or
mock-transfected 293FT cells with labeled oligo, and then
added cell lysate from 293FT cells expressing A3G (Figure
6A). Addition of a 4:1 ratio of crude MOLT4 lysate to A3G-
expressing lysate led to a 26% reduction in activity relative to
293FT, while a 9:1 ratio reduced activity by 98% (Figure 6A,
graph). Immunoblots of calreticulin showed similar levels of
this cellular protein in 293FT and MOLT4 lysates (Figure 6A,
Figure 4. Endogenous A3G Immunoprecipitated from T Cell Lines Exhibits Very Low Specific Deaminase Activity Compared to Exogenous A3G
Immunoprecipitated from Transfected Epithelial-Derived Cell Lines
(A) Parallel IPs were performed using either specific A3G antisera (A) or a rabbit non-immune control (N) for H9 T cells, H9 T cells expressing the HIV
genome containing a deletion in Vif (H9-HIV), CEM T cells, or 293FT cells transfected with the indicated amounts of A3G plasmid DNA (pA3G). Parallel
aliquots of immunoprecipitation eluates were used to determine A3G deaminase activity using the FRET assay (35 ll; graph) and for western blots (10
ll; WB). FRET signal obtained from non-immune IPs was subtracted from signal obtained from the A3G IPs for each sample.
(B) Specific deaminase activity of A3G (RFU/ng A3G protein) was determined for the indicated samples from (A). Below, western blots show amount of
A3G in each immunoprecipitation and in known recombinant standards (rA3G), which were used to determine protein amounts for specific deaminase
activity calculations.
All panels are representative of at least three independent experiments. All FRET assays were performed with RNase A. Numbers on/above bars indicate
actual values graphed.
doi:10.1371/journal.ppat.0030135.g004
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Inhibitor of A3G in T Cellsblots). These data suggested the presence of an inhibitor in
the MOLT4 cell line that can alter the activity of A3G
expressed by transfection of epithelial cell lines. Further-
more, this inhibitor is not likely to be DNA or RNA, because
inhibition was not altered by DNase (unpublished data) or by
the RNase present in the assay.
We also examined whether the inhibitor is present in an
additional A3G-deﬁcient T cell line (SupT1). We altered our
protocol so that A3G-expressing and A3G-deﬁcient lysates
were incubated together prior to the addition of oligo, and
we examined lower amounts of A3G plasmid transfected into
293FT cells to more closely approximate physiological
conditions. Addition of SupT1 cell lysate, but not lysate from
non-transfected epithelial cell lines, produced a dose-
dependent decrease in activity of transfected A3G at all
levels of expression (Figure 6B). Notably, when A3G was
expressed at approximately physiological levels (Figure 6B, 10
ng of A3G plasmid) in 293FT cells, a 1:1 ratio of crude T cell
lysate to crude A3G-expressing 293FT lysate was sufﬁcient to
inhibit the deaminase activity of transfected A3G by 50%,
and a 4:1 ratio reduced transfected A3G activity to back-
ground levels. As expected, proportionately less inhibition
was seen when lysate was added to 293FT cell lysate
expressing A3G at higher than physiologic levels (Figure 6B,
30 ng and 60 ng of A3G plasmid; also Figure 6A). Note that in
this experiment, transfection efﬁciency was high, resulting in
near saturating levels of A3G activity at 10 ng of transfected
plasmid. Despite saturating levels of A3G activity, as A3G
protein expression was increased with larger amounts of
transfection plasmid, equivalent amounts of inhibitor became
less effective. These data suggest that the inhibitor is present
in limited quantities in SupT1 cells, allowing it to be titrated
out by high levels of A3G. Moreover, although the inhibitory
activity in T cell lysates was unaffected by DNase (unpub-
lished data) or RNase, it was abolished when SupT1 lysate was
heat treated (Figure 6C). Together, these data suggest that a
protein(s) that is expressed in multiple T cell lines but not in
epithelial-derived cell lines is responsible for the observed
inhibition.
To further conﬁrm the existence of an inhibited form of
A3G in T cell lines, we partially puriﬁed LMM A3G from T
cell lines and transfected 293FT cells by velocity sedimenta-
tion. A3G protein was primarily recovered in the LMM
fractions for all cell lines after RNase A treatment followed by
velocity sedimentation (Figure 7A, blots). LMM A3G from
transfected 293FT cells displayed high levels of deaminase
activity, as expected. In contrast, even larger amounts of
LMM A3G isolated from endogenously expressing HSB2 and
Hut78 T cell lines displayed negligible deaminase activity
(Figure 7A, graph). To rule out the possibility that A3F,
another APOBEC expressed in non-transfected 293FT cells
and T cell lines, was responsible for the deaminase activity, we
used A3F-speciﬁc and A3G-speciﬁc antisera to demonstrate
that although A3F is present in crude 293FT and H9 cell
extracts, it does not co-migrate with A3G in LMM fractions
Figure 5. Endogenous A3G from Primary Human CD4þ T Cells Exhibits
Very Low Specific Deaminase Activity
(A) Deaminase activity of RNase A–treated crude cell lysates from primary
CD4þ T cells, either resting or activated for 72 h, or from 293FT cells
expressing the indicated amounts of A3G plasmid DNA (pA3G) was
determined using the FRET-based assay and is graphed. Below, western
blots (WB) show amount of A3G and the loading control calreticulin in
equivalent aliquots of cell lysates. Background fluorescence obtained
using the 13-mer GGG-containing oligonucleotide was subtracted from
the signal detected using the 13-mer CCC-containing substrate. Error
bars represent standard error of the mean of triplicate reactions.
Statistical significance *, p , 0.01 relative to 293FT, 10 ng; **, p , 0.05
relative to 293FT, 30 ng. Numbers on/above bars indicate actual values
graphed.
(B) Parallel IPs were performed using either specific A3G antisera (A) or a
rabbit non-immune control (N) for resting or activated CD4þ T cells or
293FT cells transfected with 10 ng A3G plasmid DNA (10 ng 293FT).
Parallel aliquots of immunoprecipitation eluates were used to perform
activity assays using the FRET assay (graph; 35 ll) and for western blots
(WB; 10 ll). Signals obtained from non-immune IPs were subtracted from
the A3G IPs for each sample. Western blots of 5% total immunopreci-
pitation input (T) is included for reference. Numbers on/above bars
indicate actual values graphed.
(C) Crude lysates from resting and activated primary CD4þ T cells were
subjected to velocity sedimentation without RNase treatment, fractio-
nated (1–12), and analyzed by western blotting with antibody to A3G.
Bars indicate migration of HMM and LMM forms of A3G.
All panels, except (C), are representative of at least three independent
experiments. All FRET assays were performed with RNase A.
doi:10.1371/journal.ppat.0030135.g005
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Inhibitor of A3G in T Cells(Figure 7B). This ﬁnding is consistent with previous observa-
tions that A3F-containing HMM complexes are more RNase
resistant than A3G-containing HMM complexes [37]. Thus,
these results, which were obtained using an independent
method, further demonstrate the existence of an enzymati-
cally inhibited form of A3G in T cells.
Finally, we investigated whether the A3G inhibitor resides
in the cytoplasm or in the nucleus of T cells. Microscopic
examination of crude cell lysates revealed that they are
largely free of nuclei following clariﬁcation (unpublished
data). Nevertheless, it is possible that small amounts of
nuclear contents leak into the supernatant prior to this
clariﬁcation step. To examine the subcellular localization of
the inhibitor, we mixed aliquots of LMM gradient fractions
prepared from 293FT cells expressing A3G with either
cytoplasmic or nuclear extracts (containing 5 lg of total
protein) from non-transfected 293FT cells or MOLT4 cells, a
T cell line that does not express signiﬁcant quantities of A3G
(see Figure 3A). Addition of the MOLT4 cytoplasmic extract
inhibited deaminase activity of A3G expressed exogenously in
293FT cells to a much greater extent than did cytoplasmic
extract from non-transfected 293FT cells (Figure 7C), con-
sistent with the results displayed in Figure 6. In contrast,
when the same amount of total protein was added in the form
of nuclear extract from either MOLT4 or 293FT cells, little
inhibition of A3G activity was observed (Figure 7C). These
data suggest that T cell cytoplasm, rather than T cell nuclei, is
the primary source of the inhibitory activity. Thus, it is
unlikely that leakage of nuclear contents during harvest
accounts for inhibition of A3G deaminase activity in T cells.
Discussion
In this study, we used two different cytidine deaminase
assays—a previously described gel-based assay and a novel
FRET-based assay—to compare A3G enzymatic activity in
both exogenously and endogenously expressing cells.
Although previous studies have documented deaminase
activity in several cell types, including T cell lines and
primary peripheral blood mononuclear cells (PBMCs) [30,31],
the present study constitutes the ﬁrst report to our knowl-
edge in which deaminase activity of A3G, expressed endoge-
nously or by transfection and normalized to the amount of
Figure 6. T Cell Lysates Inhibit Deaminase Activity of Exogenously
Expressed A3G in 293FT Cell Lysates
(A) Diagram explains experimental design. Lysate containing 4 or 9 lgo f
total cellular protein from non-transfected 293FT or MOLT4 cells was pre-
incubated for 15 min with the dCdC- containing oligonucleotide (labeled
with reporter [R] and quencher [Q] fluorophores), followed by the
addition of lysate containing 1.0 lg of cellular protein from 293FT cells
transfected with 1.0 lg of A3G plasmid DNA. Western blots show the
amount of A3G protein in each lysate along with calreticulin (Cal.) as a
loading control. A3G deaminase activity was then determined using the
FRET-based assay. Activity measurements are graphed as percent of the
activity of the 293FT control (to which non-transfected 293FT lysate was
added). Numbers on/above bars indicate actual values graphed.
(B) Lysate containing 1.0 lg of total cellular protein from 293FT cells
transfected with the indicated amounts of A3G plasmid DNA was
combined with the indicated amounts of lysate from A3G-deficient Sup
T1 cells (representing 0, 1, 4, or 9 lg cellular protein). Total cellular
protein in each sample was adjusted to 10 lg by adding lysate of non-
transfected, A3G-deficient 293FT cells. Total cellular protein amounts (lg)
for each of the three cell lysates separated by colons are indicated in box.
A3G deaminase activity was then determined using the FRET assay and is
graphed. Statistical significance relative to the A3G-deficient 293FT
control (i.e., the 1:0:9 point), * p , 0.01, ** p , 0.001. Error bars represent
standard error of the mean of triplicate reactions.
(C) Lysate containing 1.0 lg of total cellular protein from 293FT cells
transfected with the indicated amounts of A3G plasmid was combined
with lysate containing 9 lg of total cellular protein derived from either
non-transfected 293FT cells (open bars), SupT1 cells (grey bars), or SupT1
cells that were lysed and heated at 60 8C for 30 min (black bars). A3G
deaminase activity was then determined using the FRET-based assay and
is graphed. Statistical significance relative to 293FT control, * p , 0.01.
Error bars represent standard error of the mean of triplicate reactions.
All FRET assays were performed with RNase A. Background fluorescence
obtained using the 13-mer GGG-containing oligonucleotide was
subtracted from signal detected using the 13-mer CCC-containing
substrate.
doi:10.1371/journal.ppat.0030135.g006
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Inhibitor of A3G in T CellsA3G protein, is directly compared in a variety of different cell
types. Surprisingly, we found that for comparable amounts of
A3G protein, enzymatic activity is much lower in T cell lines
(Figures 2–4) and in resting or activated primary T cells
(Figure 5) than it is in epithelial-derived cell lines. These
ﬁndings are consistent with a model in which (1) T cells
contain an inhibitor of A3G activity, (2) epithelial-derived cell
lines contain an activator of A3G activity, or (3) T cells
contain a less active isoform of A3G. In support of the model
in which an A3G inhibitor is expressed in T cells, we
demonstrated that in the presence of RNase A or DNase,
addition of lysate from A3G-deﬁcient T cell lines (SupT1 or
MOLT4) inhibits activity of A3G expressed in epithelial cells
(Figures 6 and 7C), whereas addition of lysate from epithelial-
derived cell lines did not activate A3G from T cells. The
ability of T cell lysates to confer inhibition to A3G expressed
exogenously in 293FT cells also argues against an alternate
isoform of A3G being present in T cells. Thus, these data
suggest that when A3G is in the LMM form, i.e., in resting T
cells or following conversion by RNase treatment [5], it is
capable of being inhibited by an RNase-insensitive factor(s)
that is present or enriched in human T cells but not in
epithelial-derived cell lines.
Experiments examining deaminase activity, taken together
with experiments examining inhibition of deaminase activity
by T cell lysates, suggest that the inhibitor is active in at least
six T cell lines (H9, CEM, HSB2, Hut78, MOLT4, and SupT1),
as well as in resting and activated peripheral blood CD4þ T
cells. Moreover, our studies suggest that the inhibitor most
likely resides in the cytoplasm of T cells, which is where the
vast majority of A3G is localized [38], rather than in the
nucleus (Figure 7D), although additional studies will be
needed to verify this. Furthermore, these studies suggest that
the inhibitor is either absent, present in lower abundance, or
much less active in the transformed epithelial cell lines that
we examined (293FT and HeLa). Whether the inhibitory
factor is present in macrophages or other non-hematopoietic
cell lines remains to be determined. Moreover, its exact
mechanism of action is not known, although our studies
indicate that it is insensitive to RNase A and DNase, but is
sensitive to heat. These data suggest that the inhibitor is
either a protein that interacts with A3G or an enzyme that
modiﬁes A3G post-translationally. Recent studies have found
numerous proteins associated with A3G, although the
majority interact with it in an RNA-dependent manner
[23,39,40] and are therefore unlikely to constitute the
Figure 7. Active and Inhibited A3G Can Be Purified by Velocity
Sedimentation
(A) HMM A3G fractions from Hut78, HSB2, 293FT cells, or 293FT cells
transfected with A3G plasmid DNA (293FT-A3G) were isolated, treated
with RNase A, subjected to velocity sedimentation, and fractionated (1–
12). Each fraction was assayed by both the FRET-based deaminase assay
(graph) and by western blotting (WB). Migration of LMM A3G is indicated
by brackets.
(B) HMM A3G from 293FT cells, 293FT cells transfected with A3G plasmid
DNA, 293FT cells transfected with A3F plasmid DNA, and H9 cells were
treated with RNase and subjected to velocity sedimentation and
fractionated. Aliquots of crude cell lysates and pooled gradient fractions
3–8 (LMM) were analyzed by western blot (WB) with antiserum specific to
A3G, A3F, or calreticulin (Calretic.), and are shown below.
(C) Cytoplasmic (Cyt) and nuclear (Nuc) extracts were prepared from
either 293FT or MOLT4 T cells. Five lg of total protein from each extract,
or water (-), was mixed with aliquots of pooled gradient fractions 3–8
from A3G-transfected 293FT cells containing 6 lg A3G (A and B), and
A3G deaminase activity was determined using the FRET assay and was
graphed. Below, western blots (WB) performed in parallel show the
amount of A3G and the cellular control calreticulin (Calretic.) in each
reaction. Note that the small amount of inhibition of deaminase activity
seen upon addition of 293FT cytoplasmic extract and both nuclear
extracts is most likely due to high levels of total protein input, which we
previously observed to be mildly inhibitory (see Figure 3B). In an
independent experiment (bottom), cytoplasmic extracts (Cyt) and
nuclear pellets (NP) were analyzed for calreticulin (Calretic.) and the
nuclear marker histone 2B (H2B). Error bars represent the standard error
of the mean from triplicate reactions. Numbers on/above bars indicate
actual values graphed.
(A and C) All FRET assays were performed with RNase A. Background
fluorescence obtained using GGG-containing oligonucleotides was
subtracted from signal detected using the CCC-containing substrate.
doi:10.1371/journal.ppat.0030135.g007
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Inhibitor of A3G in T Cellsinhibitor described here. Similarly, other studies found that
A3G associates with proteins that reside in P bodies in T cell
lines and primary T cells, but these associations were also
RNA dependent [40,41].
Although it is known that the deaminase activity of
exogenously expressed A3G is inhibited when A3G associates
with RNA in HMM complexes [5,20] and that large
ribonucleoprotein complexes are present in T cells [21],
other mechanisms for regulating A3G activity could also exist,
especially given that A3G is in the LMM form in resting T
cells. In fact, multiple mechanisms of post-translational
regulation have been described for proteins related to A3G,
including APOBEC1 and activation-induced deaminase (AID)
[42–47]. Thus, the host cell likely has multiple mechanisms for
regulating A3G, especially given that APOBEC family
members with unchecked deaminase activity can be muta-
genic, causing tumors in vivo (reviewed in [48]). While some
immunoﬂuorescence studies have demonstrated an exclu-
sively cytoplasmic location for A3G in epithelial cell lines
(offering one potential mechanism to protect the host
genome) [38,49], another study reported that small amounts
of A3G are present in nuclear fractions isolated from the H9
T cell lines [9], suggesting that A3G may undergo nuclear
shuttling in response to speciﬁc stimuli or by a novel
mechanism. Since A3A, A3B, A3C, and A3H are known to
localize to the nucleus [49], it is clear that other mechanisms
besides cytoplasmic localization are used to protect the host
genome from A3 proteins. Moreover, expression of A3G in
yeast resulted in mutation of the yeast genome [50]. This
indicates that A3G can enter the nucleus in eukaryotic cells,
and suggests that mechanisms for tightly regulating A3G
deaminase activity are likely to exist [51]. Thus, the RNase-
insensitive inhibition of A3G deaminase activity reported
here is not completely surprising. Moreover, analogous forms
of regulation, acting on other APOBEC3 family members,
could exist. Little is known about the regulation of the related
proteins A3F, which also has anti-retroviral activity [52], and
A3A, A3B, and A3C, which act against endogenous retroele-
ments [53–56]. Use of the FRET-based, high-throughput assay
described here with modiﬁcations in the substrate sequence
should permit assessment of whether other APOBEC3
proteins also exhibit reduced enzymatic activity when ex-
pressed endogenously.
Notably, the presence of a factor that inhibits activity of
A3G in T cells is consistent with data from other groups
suggesting that deamination by A3G may not be required in
order for A3G to be active [5,16–19]. Others have shown that
partial antiviral activity exists even when A3G enzymatic
activity is mutationally inactivated [16–19]. Our data, taken
together with studies of others [5,57], raise the possibility that
enzymatic activity of wild-type A3G expressed in vivo may be
inactivated by a naturally occurring inhibitor that reduces
hypermutation but does not eliminate antiviral action.
Although a detailed understanding of the effects of such an
inhibitor must await its identiﬁcation, such a mechanism for
modulating A3G-mediated deamination could have multiple
implications for our understanding of HIV pathogenesis.
Since A3G can exert anti-HIV effects both when it is
packaged into virions by producer cells and when it is
present in resting T cells that are targets of infection, the role
for an inhibitor may be different in these two contexts. The
implications of an A3G inhibitor that is active in resting T
cells is more obvious. The unexpected observation that HIV
reverse transcripts isolated from resting T cells contain fewer
mutations than expected from studies of A3G activity in
epithelial cell lines [5] could be explained by the presence of a
cellular inhibitor that blocks the A3G deaminase activity of
LMM A3G, but does not inhibit antiviral activity that results
from other mechanisms of A3G action.
On the other hand, a role for an inhibitor is less clear when
A3G is packaged into virions. In the absence of Vif, HIV
cannot initiate a productive infection in T cells. Reverse
transcripts from DVif virons produced by H9 T cells show
evidence of hypermutation [58], suggesting that the inhib-
itory factor must be removed or inactivated upon packaging
of A3G into the virion or following initiation of reverse
transcription. However, given that A3G that is packaged into
virions can exert a deaminase-independent inhibitory effect
on HIV replication [17,18], it is possible that some packaged
A3G remains associated with the inhibitory factor and
partially reduces A3G enzymatic activity. Further studies will
be necessary to distinguish between these possibilities.
It is not yet known if and when this inhibitor acts in vivo.
Numerous studies have detected G-to-A hypermutation with
varying frequency in sequences from infected patient PBMCs
[59,60–63]. A single study examined the percentage of
potential A3F and A3G target sequences (GA and GGo n
the coding strand, respectively) that were altered within 70
hypermutated sequences and identiﬁed sequences containing
from 20% to 94% G-to-A substitution at these motifs [60].
Hypermutation in patient samples could result from the
generation of viral variants that lack Vif and consequently
package A3G into virions [64], or, alternatively, from Vif-
independent A3G activity in resting T cells [5]. Notably,
striking variability in the amount of hypermutation has been
observed both in samples from infected patients and in T
cells infected with Vif-encoding wild-type virus in vitro
[20,60]. In one study, the level of G-to-A hypermutation
observed upon infection of CD4þT cells with wild-type virus
in vitro depended on the timing of infection relative to T cell
activation [60], and therefore cannot be easily explained by
sporadic generation of viral variants encoding mutations in
Vif. In contrast, the RNase-independent inhibitor of A3G
deaminase activity in T cells described here could account for
at least some of the variability in G-to-A hypermutation
observed upon infection of resting T cells, both in vitro and
in patient samples. One implication of our ﬁndings is that
such physiologic regulation of deaminase activity may need to
be taken into account in studies correlating A3G mRNA and
protein expression to pathogenesis. For example, variation in
regulation of A3G deaminase activity in T cells could have
contributed to conﬂicting results of studies addressing the
consequences of A3G expression levels and polymorphisms
for HIV disease susceptibility and progression [65–68].
Finally, it is possible that even modest amounts of
inhibition of A3G deaminase activity in primary cells could
have implications for the outcome of HIV infection in vivo.
Others have suggested that sporadic inactivating mutations in
Vif may generate a reservoir of diverse sequences that may
function as a ‘‘genetic resource’’ to facilitate viral evolution
[12,64]. While high levels of A3G activity would be expected to
result in complete failure of virus propagation with antiviral
consequences, reduced levels of A3G activity could result in
virus that is viable and in fact exhibits increased rates of viral
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Inhibitor of A3G in T Cellsevolution due to the modest increase in mutation. Further
study will be required to determine if the inhibitor described
here can reduce the activity of endogenous A3G so that it fails
to produce lethal hypermutation, and instead produces sub-
lethal levels of mutation that beneﬁt the virus by promoting
viral adaptation. If so, then strategies that disrupt the
inhibitor could help to increase T cell intrinsic immunity to
HIV infection.
Materials and Methods
Plasmids. All A3G plasmids transfected in this study were
untagged. For exogenous expression of A3G, a construct obtained
from National Institutes of Health (NIH) AIDS Research and
Reference Reagent Program (catalog #9904, https://www.aidsreagent.
org/; [10]) was modiﬁed to include Kozak’s consensus sequence and to
remove the MycHis tag. Data shown here were also conﬁrmed using
an A3G plasmid that was modiﬁed to correspond to the A3G cDNA
sequence variant obtained from T cells [34], by using site-directed
mutagenesis to mutate A1448 to G and T2071 to G. Constructs
containing point mutations in the ﬁrst and second A3G deaminase
domains were obtained from Michael Malim (King’s College, London,
United Kingdom) [17] and modiﬁed to include the Kozak’s sequence.
All coding regions were conﬁrmed by sequencing.
Cell culture, transfection, and harvest. Human 293FT (Invitrogen,
http://www.invitrogen.com/) or 293T (ATCC, http://www.atcc.org/)
cells were maintained in DMEM supplemented with 10% FBS and
1% pen-strep (Gibco, http://www.invitrogen.com/). Transfections
were typically performed by mixing the indicated amounts of
plasmid DNA and 15 ll of Lipofectamine 2000 (Invitrogen) in
OPTIMEM (Gibco) and adding to cells plated in 60-mm dishes in
antibiotic-free DMEM. Alternatively, for gradient puriﬁcation ex-
periments, DNA was mixed with 45 ll of Lipofectamine 2000 and
added to cells plated in 100-mm dishes. For harvests, cells were
washed 13 in cold PBS and collected 40–48 h post-transfection by
scraping in 250 ll of NP40 buffer (0.626% NP40, 10 mM Tris acetate
[pH 7.4], 50 mM potassium acetate, 100 mM NaCl) supplemented with
protease inhibitor cocktail for mammalian cells (Sigma, http://www.
sigmaaldrich.com/) with or without 10 mM EDTA, as previously
described [35]. Cells were lysed by 20 passages through a 20-gauge
catheter. Lysates were clariﬁed by centrifugation at 1,000 rpm (162g)
for 10 min in a GH 3.8 rotor using an Allegra 6R centrifuge (Beckman
Coulter, http://www.beckmancoulter.com/). Supernatants and pellets
were examined by light microscopy to conﬁrm that nuclei were
removed by clariﬁcation. Supernatants were then subjected to a 30-s
spin in a microfuge at 18,000g. The supernatants were removed again
and used as crude cell lysates. The H9, SupTI, Jurkat, MOLT4, CEM
(ATCC), and CEM-SS and C8166 (NIH AIDS Research and Reference
Reagent Program) human T cell lines, and the U937 monocyte cell
line (ATCC), were maintained in RPMI supplemented with 10% FBS
and 1% pen-strep (Invitrogen). Hut78 and HSB2 cells (ATCC) were
maintained in IMDM (Invitrogen) supplemented with 1% pen-strep
and 20% and 10% FBS, respectively. To prepare cell lysates, intact
cells were pelleted at 1,000 rpm (162g)310 min in a Beckman Allegra
6R using a GH-3.8 rotor, washed 13 in cold PBS, and lysed in 250 ll
lysis buffer per 1.5310
7 cells as described for 293FT cells. Generation
of H9 cells stably expressing HIV-1 encoding a deletion in envelope
from bp 6636 to 7216, a frameshift in Vpr created by addition of four
nucleotides at the unique NcoI site at bp 5260, a deletion in Vif
between bp 4707 and 4989, and a deletion of Nef from bp 8390 to
8661, was previously described [69].
Primary CD4þ T cell stimulation. Human blood samples were
obtained after informed consent in accordance with procedures
approved by the human ethics committee of the Benaroya Research
Institute. PBMCs were prepared by centrifugation over Ficoll-
Hypaque gradients. CD4þ T cells were puriﬁed by depletion of cells
expressing CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRc/d,
and CD235a with the CD4þ No-touch T cell isolation kit (Miltenyi
Biotec, http://www.miltenyibiotec.com/). Cells were cultured in RPMI
supplemented with 10% pooled human serum only or were activated
in culture by the addition of 500 ng/ml PMA (Sigma) and 325 IU/ml
IL-2 (Chiron, http://www.chiron.com/). Cells were harvested after 72 h
for activity measurements. For proliferation assays, cells were
cultured in 96-well plates (30,000–50,000/well) for 72 h at 37 8C with
1 lCi [
3H]thymidine added for the last 20 h of incubation. Cells were
harvested and
3H uptake was measured on a 1450 Microbeta Plus
liquid scintillation counter (Wallac, http://las.perkinelmer.com/).
FRET-based activity assay from cell lysate. Quantiﬁcation of total
protein in cell lysates was performed using the BCA protein assay kit
(Pierce, http://www.piercenet.com/) according to the manufacturer’s
protocol. For each sample, activity was measured in triplicate for 2-
fold serial dilutions ranging from 0.078 lgt o2 0lg of total protein.
Typically, four to eight dilutions were assayed for each condition.
Assays were performed in 96-well iQ PCR plates (Bio-Rad, http://www.
bio-rad.com/) using 6-FAM- and TAMRA-labeled custom Taqman
probes (Applied Biosystems, http://www.appliedbiosystems.com/). Se-
quences are shown in Table S1. To each well was added 10 ll of cell
lysate in NP40 buffer and 70 ll of a master mix containing 10 pmol
Taqman probe, 0.4 units uracil DNA glycosylase (NEB, http://www.
neb.com/), 50 mM Tris (pH 7.4), and 10 mM EDTA. For RNase
treatment, RNase A (Qiagen, http://www.qiagen.com/) was added to
the master mix to a ﬁnal concentration of 250 lg/ml. For DNase
treatment, lysates were prepared in EDTA-free lysis buffer to which
10x start buffer and RQ RNase-free DNase (0.5 U/100 ul; Promega,
http://www.promega.com/) were added. Lysates were incubated at 37
8C for 15 min and then the DNase was inactivated by addition of 10x
stop buffer. The plates were incubated at 37 8C for 1.5–2 h followed
by addition of 4 ll of 4N NaOH and incubation for 30 min at 37 8C.
The wells were then neutralized by additional of 4 ll of 4N HCl and
36 ll of 2 M Tris (pH 7.9). The plates were cooled to 4 8C and
ﬂuorescence was measured using an iCycler (Bio-Rad) using the 490
nM FAM setting. Standard cleavage curves were prepared by mixing
different ratios of dual-labeled probe with two singly labeled half
probes to generate a linear, highly reproducible 10-fold increase in
signal over the range of 0% to 100% cleavage (Figure S1). For Figures
2A and 3–7, background ﬂuorescence obtained for each sample using
GGG-containing oligonucleotides was subtracted from the signal
detected using the CCC-containing substrate. Alternatively, in
Figures 2B and S3, the activity present in non-transfected HeLa cells
using a CCC-containing oligo was subtracted from all samples.
Protein expression was analyzed by SDS-PAGE followed by transfer to
a nitrocellulose membrane (GE Osmonics, http://www.osmolabstore.
com/). Western blotting was performed with antisera speciﬁc for
human A3G [17] and a monoclonal antibody to calreticulin (Afﬁnity
Bioreagents, http://www.bioreagents.com/), a loading control protein,
followed by detection with alkaline phosphatase-conjugated anti-
rabbit IgG and incubation with Western Blue substrate. A3F
antiserum used for western blotting was a gift of Michael Malim.
Antisera to histone 2B (Upstate, catalog number 07–371, http://www.
upstate.com/) was used as a nuclear marker.
Gel-based activity assay from cell lysate. For each sample, 5 llo f
cell lysate containing 10 lg of total cellular protein was added to 20 ll
of assay buffer containing 50 mM Tris, 10 mM EDTA, and 0.1 pmol
IR700-labeled oligonucleotide at pH 7.4 and incubated at 37 8C for 2
h. Reactions were stopped by addition of 15 ll of stop buffer and
heating to 95 8C as previously described [24]. Samples were then
electrophoresed on 15% TBE-urea polyacrylamide gels (Bio-Rad).
The IR700 infrared tag was detected by a LI-COR infrared scanner
(LI-COR Biosciences, http://www.licor.com/) and quantitated by
ImageJ software.
Immunoprecipitations. Clariﬁed cell lysates (containing 300–500
lg of total protein) were subjected to immunoprecipitation with an
antiserum to A3G (generated against the C-terminal 29 amino acids
of human A3G and described previously [17] that was afﬁnity puriﬁed
against the A3G peptide or rabbit IgG coupled to protein A
immobilized on Tris Acryl beads (Pierce) as described previously
[35,70]. After washing, all buffer was removed by aspiration. For assay
of eluted A3G, the beads were incubated for 1 h in a 37 8C shaker with
80 ll of elution buffer containing 50 mM Tris, 10 mM EDTA (pH 7.4),
and RNase A at 250 lg/ml, after which eluates were removed from
beads. Variable amounts of eluate were mixed with fresh elution
buffer to a ﬁnal volume of 70 ll. This was then added to 10 llo f
master mix containing 10 pmol Taqman probe, 0.4 units uracil DNA
glycosylase, 50 mM Tris (pH 7.4), and 10 mM EDTA, and assayed as
described for cell lysates. Alternatively, immunoprecipitations (IPs)
were performed in the presence of RNase A. Following washings,
beads were incubated for 1–2 h in a 37 8C shaker with 80 ll of activity
assay master mix containing 10 pmol Taqman probe, 0.4 units uracil
DNA glycosylase, 50 mM Tris (pH 7.4), and 10 mM EDTA. The master
mix was removed and assayed as described for cell lysates.
Velocity sedimentation. For analysis of A3G-containing complexes
(primary T cells), 80–100 ll of cell lysates were layered onto step
gradients containing 900 ll each of 10%, 15%, 20%, 30% and 50%
sucrose in NP40 buffer with EDTA and subjected to velocity
sedimentation in a Beckman MLS 50 rotor at 45,000 rpm (163000g)
for 45 min at 4 8C. Fractions (200 ll) were serially collected from the
top of the gradient, precipitated with trichloroacetic acid, and
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(293FT and H9 cells) were layered onto 5-ml continuous gradients of
5%–25% sucrose in NP40 buffer with EDTA and subjected to velocity
sedimentation in a MLS 50 rotor at 45,000 rpm for 90 min at 4 8C.
Fractions (400 ll) were serially collected from the top of the gradient
and aliquots analyzed by immunoblotting.
Isolation of LMM fractions. For 293FT cells, four 100-mm plates of
cells were lysed in 3 ml of NP40 buffer supplemented with protease
inhibitors and 10 mM EDTA, as described above. For T cells, 50310
6
cells were lysed in 3 ml of NP40 buffer supplemented with protease
inhibitors and 10 mM EDTA. For isolation of HMM complexes, 3 ml
of crude cell lysates were layered over 2 ml of 20% sucrose in NP40
buffer and subjected to velocity sedimentation in a Beckman MLS 50
rotor at 50,000 rpm (201,000g) for 80 min at 4 8C. The bottom 500 ll
was collected and sucrose was removed using 2-ml Zeba Desalt
Columns (Pierce) prewashed with NP40 buffer. The ﬂow through was
treated with RNase A (250 lg/ml) for 30 min at 26 8C, and precipitated
material was removed with a 30-s spin in a microfuge at 18,000g. For
isolation of LMM fractions, 400 ll of the RNase-treated material was
layered onto 5-ml continuous gradients of 5%–25% sucrose in NP40
buffer and subjected to velocity sedimentation in a MLS 50 rotor at
50,000 rpm for 3.5 h at 4 8C. Fractions (200 ll) were serially collected
from the top of the gradient and fractions 1–12 were analyzed by
immunoblotting.
Preparation of cytoplasmic and nuclear extracts. For adherent
cells, 10-cm conﬂuent plates were washed 13 in cold PBS and then
cells were collected by scraping in 1 ml of cold PBS. Cells were
pelleted at 1,000 rpm (162g)310 min in a Beckman Allegra 6R using a
GH-3.8 rotor and the PBS was removed. Cells were resuspended in 1
packed cell volume (PCV) of NE1 buffer (10 mM HEPES [pH 8.0], 1.5
mM MgCl2, 10 mM KCl, 1 mM DTT, 1:100 protease inhibitor cocktail)
and incubated on ice for 15 min. Cells were then sheared by ﬁve
passages through a 22-gauge needle and subjected to a 30-s spin in a
microfuge at 18,000g. The supernatant was collected and used as
‘‘cytoplasmic extract.’’ The pellet was washed 13 in an additional 1
PCV PBS. The remaining pellet was resuspended in 2/3 PCV NE2
buffer (20 mM HEPES [pH 8.0], 1.5 mM MgCl2, 25% glycerol, 420 mM
NaCl, 0.2 mM EDTA, 1 mM DTT, 1:100 protease inhibitor cocktail)
and incubated at 4 8C with shaking for 30 min, followed by a 5-min
spin in a microfuge at 18,000g. The supernatant was collected and
used as ‘‘nuclear extract.’’ The pelleted material was designated
‘‘nuclear pellet.’’ For suspension cultures, cells were pelleted and
washed 23 in cold PBS. Extracts were prepared as described for
adherent cells.
Lysate mixing experiments. Lysates from A3G-transfected 293FT
cells, non-transfected 293FT cells, and A3G-deﬁcient T cell lines were
prepared as previously described. In Figure 6A, lysates containing 4
or 9 lg of protein from either the MOLT4 T cell line or 293FT cells
were pre-incubated with the FRET assay master mix containing
labeled oligo, RNase, and UDG for 15 min at 37 8C. One lg protein
from 293FT cells expressing A3G was added per well and the
reactions were incubated at 37 8C for an additional 1.5 h. In Figure
6B, lysates containing 0, 1, 4, or 9 lg of protein from the SupT1 T cell
line was mixed with 1 lg of protein from 293FT cells expressing A3G.
Lysate from non-transfected 293FT cells was added to bring the total
protein to 10 lg. Mixed lysates were incubated for 1 h at 37 8C and
then FRET assay master mix was added. In Figure 6C, lysates from
non-transfected 293FT or SupT1 cells were heated at 60 8C for 30 min
or held on ice prior to mixing with lysates from transfected 293FT
cells. Mixed lysates were incubated for 1 h at 37 8C and then FRET
assay master mix was added. For Figure 7C, nuclear and cytoplasmic
extracts were prepared as described above. For each condition, 5 lg
of nuclear or cytoplasmic protein from 293FT or MOLT4 cells or
water was mixed with 2 ll of pooled LMM fractions 3–8 prepared as
described above for A3G-transfected 293FT cells. The mixed lysates
were incubated for 1 h at 37 8C and then FRET assay master mixes
containing either the 21-mer ACCCA or 21-mer GGG oligo were
added.
Quantitation of speciﬁc activity. To calculate speciﬁc activity,
deaminase activity was measured using different amounts of input
(1.25 to 10 lg of total cellular protein) to generate dose-response
curves for T cell lines and a comparable epithelial cell line control.
Western blotting was used to determine the amount of A3G in 10 lg
of total cellular protein (the highest point in the linear range) for
each cell type. A standard curve was generated by western blotting
different amounts of puriﬁed recombinant A3G in parallel with cell
lysate samples. A3G bands on western blots were quantiﬁed by
densitometry, and ng amounts of A3G were determined for each
sample by interpolation on the standard curve of recombinant A3G
(Figure S3). For each cell type, deaminase activity of the 10-lg sample
was divided by A3G protein content of that sample to obtain the
speciﬁc deaminase activity.
For densitometry, immunoblots were scanned using a Cannon
8400F scanner and quantitated relative to recombinant standards
(produced by ImmunoDiagnostics, http://www.immunodx.com/, NIH
AIDS Research and Reference Reagent Program catalog #10067)
present on the same blot using Adobe Photoshop. Statistical analyses
were performed using a Student’s t-test (one tailed, assuming unequal
variances).
Supporting Information
Figure S1. A Quantitative, High-Throughput FRET-Based Assay for
Measuring A3G Deaminase Activity
(A) Schematic diagram depicting the FRET-based A3G activity assay.
(1) In transfected 293T cells, A3G exists in an enzymatically inactive,
HMM complex and is unable to deaminate the CCC-containing
oligonucleotide substrate. The substrate remains uncleaved through-
out subsequent steps, and consequently, the reporter ﬂuorophore (R)
is quenched by the quencher ﬂuorophore (Q) and background
ﬂuorescence is detected. (2) In transfected 293T cells, RNase A
treatment disrupts the HMM complex, converting A3G to an LMM,
enzymatically active form. Upon incubation with substrate, deami-
nation by A3G results in conversion of dC residues to dUs (a).
Treatment with uracil DNA glycosylase (UDG) leads to removal of
dUs to create abasic sites (b). At high pH, the substrate is cleaved at
the site of deamination (c), dissociating the reporter and quencher
ﬂuorophores and creating a ﬂuorescent signal that can be detected by
a luminometer (d). Note that depending on the oligo used, other
detection methods can be used in step (d) to measure deaminase
activity, as in Figure 1. (B) Standard cleavage curves were prepared by
mixing different ratios of dual-labeled oligonucleotides with two
singly labeled half oligonucleotides (shown in Table S1 as 6-FAM half
probe and TAMRA half probe) to simulate a range from 0% to 100%
cleavage (% free reporter). Graph shows RFU measurements for each
ratio of probes. Error bars represent standard error of the mean from
triplicate samples.
Found at doi:10.1371/journal.ppat.0030135.sg001 (52 KB PDF).
Figure S2. Validation of the FRET-Based Assay by Measuring
Exogenous Wild-Type and Mutant A3G Transfected into Epithelial
Cell Lines
(A) Activity measurements using the FRET-based assay were
performed on lysates of 293FT cells transfected with increasing
amounts of A3G plasmid DNA, as indicated. Assays were performed
either with (þ) or without (-) RNase A, using a 13-base oligonucleotide
substrate either containing the A3G recognition sequence (CCC) or
lacking dCs (GGG), as indicated. A3G deaminase activity is graphed
for each condition. A3G expression was assessed by western blot (WB)
of three amounts of total cellular protein input (10, 30, and 90 lg),
with western blots of calreticulin (Calretic.) as a loading control. (B)
A3G deaminase activity using the FRET-based assay was determined
for increasing amounts (as indicated by amount of total cellular
protein in lg) of RNase A–treated cell lysate obtained from 293FT
cells transfected with 100 ng of A3G plasmid using oligonucleotide
substrates (listed in Table S1) ranging in length from 13 to 19 bases or
13-base substrates lacking the A3G recognition sequence (GGG or
GTC) as indicated. A3G deaminase activity is graphed, showing a dose
response with increasing amounts of A3G lysate only when substrates
containing the canonical A3G recognition sequence (CCC) were used.
(C) Non-transfected 293FT cells, or 293FT transfected with either
A3G and A3F plasmid DNA, was analyzed by western blot using
antiserum speciﬁc for A3G, A3F, and the loading control calreticulin.
(D) Lysates from 293FT cells expressing A3G were subjected to
parallel immunoprecipitations using antiserum speciﬁc for A3G or a
non-immune control. A3G was eluted in the presence of RNase A and
A3G deaminase activity from increasing amounts of the eluates was
determined using the FRET-based assay using a 13-base CCC-
containing oligonucleotide. The ﬂuorescent signal from a matched
non-immune immunoprecipitation was subtracted from each A3G
immunoprecipitation and is graphed. Graph shows a dose response
obtained from increasing input amounts of A3G speciﬁc elution. (E)
Deaminase activity of RNase A treated lysates from 293FT cells
expressing either wild-type (WT) A3G or A3G constructs encoding
point mutations in both A3G catalytic sites was determined using the
FRET-based assay and was graphed. Background ﬂuorescence
obtained using a GGG-containing oligonucleotide was subtracted
from each sample. Below, western blot analysis of equivalent amounts
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loading control. Similar results were observed following immuno-
precipitation of these mutants (unpublished data). Statistical signiﬁ-
cance relative to WT, * p , 0.02, ** p , 0.03. Error bars represent
standard error of the mean from triplicate reactions.
Found at doi:10.1371/journal.ppat.0030135.sg002 (206 KB PDF).
Figure S3. Example Calculation of Speciﬁc Deaminase Activity
(A) A3G content of each sample was determined by subjecting the cell
lysates as well as known amounts of recombinant A3G (ng rA3G) to
western blotting with antibody to A3G. Densitometry of the rA3G
bands was used to create a standard curve of A3G protein amounts
and to determine the linear range of the western blot (graph). The
amount of A3G for each sample (HeLa-A3G, H9, and CEM) was then
determined by interpolation on this graph. (B) Deaminase activity
was determined over a range of input amounts (1.25–10 lg total
cellular protein) for RNase A–treated crude cell lysates from the T
cell lines H9 and CEM as well as HeLa cells transfected with 3 lgo f
A3G plasmid (graph). Speciﬁc activity calculations for all samples
were performed for the total protein amount (10 lg) corresponding
to the high end of the linear range for activity of transfected HeLa
cells. Background ﬂuorescence obtained for each sample using a non-
transfected HeLa control was subtracted from each sample to obtain
the corrected deaminase value (indicated on graph for 10-lg inputs).
Speciﬁc activity was calculated by dividing the corrected deaminase
value in RFU by the amount of A3G protein (ng A3G). The speciﬁc
activity for these samples are graphed in Figure 2B.
Found at doi:10.1371/journal.ppat.0030135.sg003 (218 KB PDF).
Table S1. Oligonucleotide Probe Sequences
Target motifs are in bold.
Found at doi:10.1371/journal.ppat.0030135.st001 (17 KB XLS).
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